{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:36:31Z","timestamp":1784846191454,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M773592"],"award-info":[{"award-number":["2025M773592"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M781897"],"award-info":[{"award-number":["2025M781897"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L248087"],"award-info":[{"award-number":["L248087"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L234044"],"award-info":[{"award-number":["L234044"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7252206"],"award-info":[{"award-number":["7252206"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L246051"],"award-info":[{"award-number":["L246051"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019063","name":"Tianjin Municipal Enterprise Technology Commissioner Project","doi-asserted-by":"publisher","award":["24YDTPJC00350"],"award-info":[{"award-number":["24YDTPJC00350"]}],"id":[{"id":"10.13039\/501100019063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2024-12M-ZH-009"],"award-info":[{"award-number":["2024-12M-ZH-009"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2025-I2M-XHJC-026"],"award-info":[{"award-number":["2025-I2M-XHJC-026"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2023-I2M-2-006"],"award-info":[{"award-number":["2023-I2M-2-006"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2025-I2M-XHXX-098"],"award-info":[{"award-number":["2025-I2M-XHXX-098"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014883","name":"China National Nuclear Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011176","name":"Peking Union Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502399"],"award-info":[{"award-number":["82502399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372002"],"award-info":[{"award-number":["82372002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22507148"],"award-info":[{"award-number":["22507148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2022-RC350-04"],"award-info":[{"award-number":["2022-RC350-04"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010041","name":"Tianjin Municipal Science and Technology Committee","doi-asserted-by":"publisher","award":["25ZXRKSY00020"],"award-info":[{"award-number":["25ZXRKSY00020"]}],"id":[{"id":"10.13039\/501100010041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.phrs.2026.108138","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T15:57:57Z","timestamp":1771084677000},"page":"108138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["First-in-human evaluation of four novel PSMA-targeted PET radiotracers with non-canonical amino acid linkage: A comparative study"],"prefix":"10.1016","volume":"225","author":[{"given":"Dong","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshuang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2026.108138_bib1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.phrs.2026.108138_bib2","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Public Health"},{"issue":"10437","key":"10.1016\/j.phrs.2026.108138_bib3","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2026.108138_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CACancer J. Clin."},{"issue":"6","key":"10.1016\/j.phrs.2026.108138_bib5","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41416-022-02136-3","article-title":"Five-year survival of patients with late-stage prostate cancer: comparison of the military health system and the U.S. general population","volume":"128","author":"Lin","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108138_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL trial","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108138_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2019.06.004","article-title":"Biochemical recurrence in prostate cancer: the european association of urology prostate cancer guidelines panel recommendations","volume":"6","author":"Van den Broeck","year":"2020","journal-title":"Eur. Urol. Focus"},{"issue":"10","key":"10.1016\/j.phrs.2026.108138_bib8","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s11912-025-01686-y","article-title":"Prostate cancer radioligand therapy: PSMA and beyond, current landscape and future directions","volume":"27","author":"Bent","year":"2025","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-023-00670-6","article-title":"Radiotheranostics in advanced prostate cancer: current and future directions","volume":"27","author":"Jia","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.phrs.2026.108138_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijrobp.2024.08.045","article-title":"Evolving paradigms in prostate cancer: the integral role of prostate-specific membrane antigen positron emission tomography\/computed tomography in primary staging and therapeutic decision-making","volume":"121","author":"Udovicich","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.phrs.2026.108138_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2967\/jnumed.124.267730","article-title":"Treatment landscape of prostate cancer in the era of PSMA radiopharmaceutical therapy","volume":"66","author":"Turco","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts","year":"2022","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib13","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.108138_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114538","article-title":"Imaging-guided targeted radionuclide tumor therapy: from concept to clinical translation","volume":"190","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.phrs.2026.108138_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061367","article-title":"PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy","volume":"12","author":"Jones","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib16","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.phrs.2026.108138_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ph14080713","article-title":"[68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer","volume":"14","author":"Hennrich","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.phrs.2026.108138_bib18","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.2967\/jnumed.124.267899","article-title":"[68Ga]Ga-PSMA-11 PET and prostate cancer bone metastases: diagnostic performance of available standardized criteria","volume":"65","author":"Mainta","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00259-015-3188-1","article-title":"68Ga-PSMA-11 PET\/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients","volume":"43","author":"Sterzing","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.phrs.2026.108138_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2967\/jnumed.119.229187","article-title":"Matched-pair comparison of 68Ga-PSMA-11 PET\/CT and 18F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy","volume":"61","author":"Rauscher","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108138_bib22","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/RLU.0000000000003425","article-title":"False-positive 18F\u2013prostate-specific membrane antigen\u20131007 PET\/CT caused by hepatic multifocal inflammatory foci","volume":"46","author":"Ladr\u00f3n-de-Guevara","year":"2021","journal-title":"Clin. Nucl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib23","article-title":"Radiotherapy toxicity","volume":"5","author":"De Ruysscher","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"8015","key":"10.1016\/j.phrs.2026.108138_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.phrs.2026.108138_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28104022","article-title":"Preclinical evaluation of a PSMA-targeting homodimer with an optimized linker for imaging of prostate cancer","volume":"28","author":"Murce","year":"2023","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/j.phrs.2026.108138_bib26","doi-asserted-by":"crossref","first-page":"21617","DOI":"10.1021\/acs.jmedchem.4c02656","article-title":"Synthesis and evaluation of 99mTc-labeled l-aspartic acid as a euk polymer linker for targeting PSMA to a novel SPECT tumor tracer","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2026.108138_bib27","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00259-024-07046-5","article-title":"Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [68Ga]Ga\/[177Lu]Lu\u2013NYM032 for theranostic use in prostate cancer","volume":"52","author":"Fu","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.phrs.2026.108138_bib28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Bene\u0161ov\u00e1","year":"2015","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108138_bib29","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA Inhibitors","volume":"59","author":"Bene\u0161ov\u00e1","year":"2016","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2026.108138_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14051098","article-title":"Design, synthesis, and evaluation of linker-optimised PSMA-targeting radioligands","volume":"14","author":"Lundmark","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.phrs.2026.108138_bib31","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/acs.molpharmaceut.2c01101","article-title":"Improve the biodistribution with bulky and lipophilic modification strategies on lys-urea-glu-based PSMA-targeting radiotracers","volume":"20","author":"Cai","year":"2023","journal-title":"Mol. Pharm."},{"issue":"18","key":"10.1016\/j.phrs.2026.108138_bib32","doi-asserted-by":"crossref","first-page":"19661","DOI":"10.1021\/acs.jmedchem.5c02083","article-title":"A novel type of PSMA-targeting ligands via \u03b2-branched aromatic \u03b1-amino acid modification, bearing enhanced tumor targeting and reduced renal toxicity","volume":"68","author":"Liu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108138_bib33","article-title":"Linker manipulation with Beta3-amino acids potentiates the efficacy and safety of PSMA radiopharmaceuticals","author":"Gao","year":"2026","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.phrs.2026.108138_bib34","article-title":"Icosahedral carborane: a safe albumin binder for augmenting radiopharmaceuticals\u2019 tumor uptake and retention","author":"Li","year":"2026","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.phrs.2026.108138_bib35","doi-asserted-by":"crossref","first-page":"25403","DOI":"10.1021\/acs.jmedchem.5c02380","article-title":"Synthesis and evaluation of cyclic peptide-based PET tracers targeting ADAMTS4 for early detection and monitoring of aortic aneurysms","volume":"68","author":"Huang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108138_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2023.111050","article-title":"Predictive value of radiomic signature based on 2-[18F]FDG PET\/CT in HER2 status determination for primary breast cancer with equivocal IHC results","volume":"167","author":"Liu","year":"2023","journal-title":"Eur. J. Radio."},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib37","first-page":"113","article-title":"Quantitative PET imaging of tumor integrin \u03b1v\u03b23 expression with 18F-FRGD2","volume":"47","author":"Zhang","year":"2006","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib38","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-016-0195-6","article-title":"Automated synthesis of [18F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models","volume":"6","author":"Bouvet","year":"2016","journal-title":"EJNMMI Res."},{"issue":"8","key":"10.1016\/j.phrs.2026.108138_bib39","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1021\/acsptsci.4c00257","article-title":"Effect of linker entities on pharmacokinetics of 111In-labeled prostate-specific membrane antigen-targeting ligands with an albumin binder","volume":"7","author":"Kazuta","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2026.108138_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ph14030277","article-title":"Species differences in microsomal metabolism of xanthine-derived A1 adenosine receptor ligands","volume":"14","author":"Schneider","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.phrs.2026.108138_bib41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2967\/jnumed.118.221150","article-title":"Albumin-binding PSMA ligands: implications for expanding the therapeutic window","volume":"60","author":"Kelly","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"21","key":"10.1016\/j.phrs.2026.108138_bib42","doi-asserted-by":"crossref","first-page":"23389","DOI":"10.1021\/acs.jmedchem.5c02183","article-title":"64Cu-labeled stapled peptide-based radiopharmaceuticals targeting MDM2\/MDMX for Pan-p53 tumors","volume":"68","author":"Tian","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108138_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2025.12.028","article-title":"Development of galectin-3 targeted radioimmunoligands for cancer theranostics","author":"Zhang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.phrs.2026.108138_bib44","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.apsb.2024.07.006","article-title":"Enhanced radiotheranostic targeting of integrin \u03b15\u03b21 with PEGylation-enabled peptide multidisplay platform (PEGibody): a strategy for prolonged tumor retention with fast blood clearance","volume":"15","author":"Zhang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.phrs.2026.108138_bib45","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0731-7085(95)01504-E","article-title":"The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs","volume":"13","author":"L\u00e1zn\u00ed\u010dek","year":"1995","journal-title":"Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2024","journal-title":"Nat. Rev. Urol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108138_bib47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2967\/jnumed.118.207993","article-title":"PSMA-targeted radionuclide therapy and salivary gland toxicity: why does it matter","volume":"59","author":"Ta\u00efeb","year":"2018","journal-title":"? J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108138_bib48","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-024-00237-3","article-title":"A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [68Ga]Ga-PSMA-11","volume":"9","author":"Huang","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2026.108138_bib49","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.semnuclmed.2016.04.006","article-title":"Renal function assessment during peptide receptor radionuclide therapy","volume":"46","author":"Erbas","year":"2016","journal-title":"Semin. Nucl. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108138_bib50","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1097\/RLU.0000000000004149","article-title":"Delayed nephrotoxicity after 225Ac-PSMA-617 Radioligand Therapy","volume":"47","author":"Satapathy","year":"2022","journal-title":"Clin. Nucl. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108138_bib51","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1021\/acsomega.4c10142","article-title":"Structure\u2013activity relationships and biological insights into PSMA-617 and its derivatives with modified lipophilic linker regions","volume":"10","author":"Sch\u00e4fer","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.phrs.2026.108138_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108945","article-title":"Structure-affinity-pharmacokinetics relationships of 111In-labeled PSMA-targeted ligands with different albumin binders","volume":"138-139","author":"Yamaguchi","year":"2024","journal-title":"Nucl. Med. Biol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108138_bib53","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00259-025-07102-8","article-title":"Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer","volume":"52","author":"Ritt","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"11","key":"10.1016\/j.phrs.2026.108138_bib54","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1007\/s00259-022-05837-2","article-title":"Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer","volume":"49","author":"Tschan","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"10.1016\/j.phrs.2026.108138_bib55","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","article-title":"Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC","volume":"48","author":"Kramer","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.phrs.2026.108138_bib56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.120.250738","article-title":"177Lu-labeled albumin-binder\u2013conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio","volume":"62","author":"Kuo","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.phrs.2026.108138_bib57","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.2967\/jnumed.116.188722","article-title":"Dual-target binding ligands with modulated pharmacokinetics for endoradiotherapy of prostate cancer","volume":"58","author":"Kelly","year":"2017","journal-title":"J. Nucl. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:37:42Z","timestamp":1778582262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":57,"alternative-id":["S1043661826000538"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108138","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human evaluation of four novel PSMA-targeted PET radiotracers with non-canonical amino acid linkage: A comparative study","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108138"}}